Table 1.
Baseline characteristics of the patients
| Age/sex | Duration of RA | Stage | Number of previous DMARDs | Previous biologics | Combination drugs | ||
|---|---|---|---|---|---|---|---|
| DMARDs | Steroid | ||||||
| Pt. 1 | 71 F | 10 years | 3 | 2 | IFX, ETN | MTX 8 mg | PSL 5 mg |
| Pt. 2 | 68 F | 28 years | 2 | 6 | None | AZP 100 mg | PSL 6 mg |
| Pt. 3 | 74 F | 16 years | 3 | 6 | ETN | None | PSL 5 mg |
| Pt. 4 | 54 F | 1 year 6 months | 2 | 1 | IFX, ETN | MTX 15.5 mg | PSL 12.5 mg |
| Pt. 5 | 51 F | 27 years | 4 | 2 | IFX | MTX 10.5 mg | PSL 5 mg |
| Pt. 6 | 49 F | 2 years | 2 | 1 | IFX | MTX 6 mg | None |
| Pt. 7 | 73 F | 1 year 3 months | 2 | 2 | None | MTX 8 mg | None |
Pt. patient, IFX infliximab, ETN etanercept, MTX methotrexate, AZP azathioprine, PSL prednisolone